Portugal’s largest drugmaker BIAL today announced an exclusive license agreement for the commercialization of Zebinix (eslicarbazepine acetate) in South Korea with local firm WhanIn Pharm (KRX: 016580), whose shares edged up 1.6% 5o 25,800 won on the news.
Eslicarbazepine acetate is BIAL’s proprietary once daily anti-epileptic for the treatment of partial-onset seizures, with or without secondary generalization.
“BIAL is committed to addressing the needs of patients and healthcare professionals worldwide and the control of seizures is a continual challenge. We are delighted to partner with WhanIn and thus be able to offer this treatment option for patients with focal epilepsy across South Korea,” comments António Portela, chief executive of BIAL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze